The US has a new most powerful laser
Business Announcement
Updates every hour. Last Updated: 15-Aug-2025 12:10 ET (15-Aug-2025 16:10 GMT/UTC)
Postpartum depression (PPD) affects up to 15 percent of individuals after childbirth. Early identification of patients at risk of PPD could improve proactive mental health support. Mass General Brigham researchers developed a machine learning model that can evaluate patients’ PPD risk using readily accessible clinical and demographic factors. Findings demonstrating the model’s promising predictive capabilities are published in the American Journal of Psychiatry.
Two new studies examining mental health risks postpartum were published online today in the American Journal of Psychiatry in conjunction with Maternal Mental Health Awareness Month and the 2025 Annual Meeting of the American Psychiatric Association (APA). One study sought to estimate the risk of postpartum depression in people without a history of depression, and the other looked at the familial contribution to the risk of postpartum psychosis. Researchers from both studies were on hand to discuss their findings at a special briefing held at the APA meeting.
PAX3 is a transcription factor (proteins involved in converting DNA into RNA) that drives melanoma progression by promoting cell growth, migration and survival, while inhibiting cellular terminal differentiation, which is the final stage where a cell becomes specialized and cell division ends. However, known PAX3 target genes are limited and cannot fully explain the wide impact of PAX3 function, suggesting that there are most likely many other genes that PAX3 controls that are undiscovered.
The PAX3 protein can regulate DNA through two separate binding domains, the paired domain (PD) and homeodomain (HD), which bind different DNA motifs, short recurring sequences within a DNA strand that regulate gene expression. It is not clear if these two domains bind and work together to regulate genes and if they promote all or only a subset of downstream cellular events.
A new study by researchers at Boston University Chobanian & Avedisian School of Medicine has discovered that PAX3 mainly uses the PD to bind to the DNA, and that it mostly turns on genes—many of which help cells grow and make other proteins – activities that support cancer growth.
Berlin, Germany – As antibiotic resistance accelerates into a global crisis, phage therapy is emerging as one of the most promising—and urgent—solutions in modern medicine. From June 10–11, 2025, the international scientific and medical community will gather in Berlin for Targeting Phage Therapy 2025, the leading global event focused on translating phage research into clinical reality.
With the theme “From Bench to Bedside: Accelerating Clinical Applications of Phage Therapy”, this year’s program brings together global leaders across infectious diseases, oncology, microbiome science, regulatory affairs, and biotechnology.